Trial Profile
A phase I/II clinical trial of Ad-SGE-REIC for malignant pleural mesothelioma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Aug 2018
Price :
$35
*
At a glance
- Drugs Ad5 SGE DKK3 gene therapy-Momotaro (Primary)
- Indications Malignant-mesothelioma
- Focus Adverse reactions
- Sponsors Kyorin Pharmaceutical
- 03 Aug 2018 Status changed from active, no longer recruiting to completed.
- 06 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 09 Jun 2016 New trial record